Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis.

DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage (2005) 2.84

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 2.03

Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol (2010) 1.41

3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler (2008) 1.39

Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol (2012) 1.27

MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol (2005) 1.26

Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging (2011) 1.24

Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab (2007) 1.16

Cognitive presentation of multiple sclerosis: evidence for a cortical variant. J Neurol Neurosurg Psychiatry (2003) 1.11

Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2005) 1.09

Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? J Neurol (2008) 1.05

Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol (2011) 1.03

Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. Eur Radiol (2011) 0.96

MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol (2009) 0.94

Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. J Neurosci (2012) 0.94

Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.91

Hippocampal volume is related to cognitive decline and fornicial diffusion measures in multiple sclerosis. Magn Reson Imaging (2013) 0.90

Relationship Between White Matter Integrity, Attention, and Memory in Schizophrenia: A Diffusion Tensor Imaging Study. Brain Imaging Behav (2009) 0.86

Multisequence-imaging protocols to detect cortical lesions of patients with multiple sclerosis: observations from a post-mortem 3 Tesla imaging study. J Neurol Sci (2009) 0.85

Superficially located white matter structures commonly seen in the human and the macaque brain with diffusion tensor imaging. Brain Connect (2011) 0.83

Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine. J Neurol (2011) 0.82

Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis. J Neurol (2015) 0.81

Grey matter lesions in MS: from histology to clinical implications. Prion (2012) 0.81

Modeling the relationship among gray matter atrophy, abnormalities in connecting white matter, and cognitive performance in early multiple sclerosis. AJNR Am J Neuroradiol (2014) 0.80

Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis. J Magn Reson Imaging (2016) 0.79

Reduced magnetisation transfer ratio in cognitively impaired patients at the very early stage of multiple sclerosis: a prospective, multicenter, cross-sectional study. BMJ Open (2014) 0.78

The Neurophysiologist Perspective into MS Plasticity. Front Neurol (2015) 0.75

The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. Front Neurol (2016) 0.75

Are Modular Activations Altered in Lower Limb Muscles of Persons with Multiple Sclerosis during Walking? Evidence from Muscle Synergies and Biomechanical Analysis. Front Hum Neurosci (2016) 0.75

Neuroradiological imaging and neuropsychological testing in multiple sclerosis. AJNR Am J Neuroradiol (2000) 0.75

Relevance of the skewness index in DTI exploration of multiple sclerosis. MAGMA (2008) 0.75

Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet (2001) 5.09

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet (2009) 4.16

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol (2001) 3.93

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37

Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21

White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med (2000) 2.62

Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology (2001) 2.24

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 2.19

Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology (2012) 2.13

Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13

Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology (2011) 2.06

Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04

Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology (2010) 2.03

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 2.00

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology (2003) 1.94

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93

MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90

Cognitive and psychosocial features of childhood and juvenile MS. Neurology (2008) 1.85

Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology (2010) 1.85

Paraplegia following coeliac plexus block. Pain (1993) 1.85

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet (1999) 1.81

Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler (2005) 1.81

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology (2008) 1.76

Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging. AJNR Am J Neuroradiol (2001) 1.75

The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology (2006) 1.72

Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol (1994) 1.72

Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. Am J Pathol (2000) 1.71

Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler (2008) 1.70

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol (2005) 1.69

A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage (2005) 1.68

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology (2011) 1.68

Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66

A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2009) 1.64

Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63

Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology (2008) 1.63

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology (2007) 1.62

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain (2003) 1.60

Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology (2010) 1.58

Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. AJNR Am J Neuroradiol (2011) 1.58

Denaturing gradient gel electrophoresis analysis of the 16S rRNA gene V1 region to monitor dynamic changes in the bacterial population during fermentation of Italian sausages. Appl Environ Microbiol (2001) 1.57

Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain (1999) 1.56

Electrophysiological and MRI evaluation of neurological involvement in Behçet's disease. J Neurol Neurosurg Psychiatry (1989) 1.54

Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol (1999) 1.54

Impedance measurements to study the antimicrobial activity of essential oils from Lamiaceae and Compositae. Int J Food Microbiol (2001) 1.52

Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry (2001) 1.51

Diffusion MRI in multiple sclerosis. Neurology (2005) 1.49

In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain (2007) 1.48

Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am J Neuroradiol (2010) 1.47

Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology (2010) 1.44

Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol (1998) 1.44

Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. J Neurol Neurosurg Psychiatry (2000) 1.43

IFCN standards for digital recording of clinical EEG. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol (1998) 1.43

Abnormal cervical cord function contributes to fatigue in multiple sclerosis. Mult Scler (2012) 1.42

The "mirror-neuron system" in MS: A 3 tesla fMRI study. Neurology (2007) 1.42

Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol (1999) 1.42

Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage (2002) 1.41

Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol (2003) 1.41

Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40

Neurodegeneration in the course of Langerhans cell histiocytosis. Neurol Sci (2011) 1.40

Failure of topical estrogen receptor agonists and antagonists to alter murine hair follicle cycling. J Invest Dermatol (1998) 1.40

Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology (2000) 1.39

Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment. Ital J Neurol Sci (1996) 1.39

A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology (1995) 1.38

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain (2000) 1.35

Effects of seasons on magnetic resonance imaging--measured disease activity in patients with multiple sclerosis. Ann Neurol (2001) 1.35

Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology (2009) 1.35

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology (1999) 1.31

The present and the future of neuroimaging in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol (2010) 1.30

MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29

Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol (2001) 1.29

Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol (1999) 1.28

Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. Brain (1996) 1.27

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology (2010) 1.27